Vistagen Therapeutics Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics for violations of securities laws, covering stock transactions from April 1, 2024, to December 16, 2025, with a deadline for claims on March 16, 2026.
- False Statements: The complaint alleges that Vistagen misled investors regarding the success of its PALISADE-2 trial, creating a false impression of the drug candidate's prospects, which adversely affected shareholder investment decisions.
- Investor Losses: Affected shareholders are encouraged to join the lawsuit to seek compensation, as DJS Law Group focuses on enhancing investor returns through aggressive legal advocacy, ensuring clients' claims are respected.
- Legal Service Advantage: DJS Law Group has extensive experience in securities class actions and corporate governance litigation, dedicated to providing efficient legal services to some of the largest hedge funds and alternative asset managers globally, helping clients maximize recovery of losses.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 0.97 USD with a low forecast of 0.90 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.671
Low
0.90
Averages
0.97
High
1.00
Current: 0.671
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
